Revvity

Revvity is one of the...

• Forbes Global 2000 (#1756);
• Fortune 500 (#682);
• Russell 3000;
• S&P 500.

Revvity is a company listed under the stock ticker RVTY (US).

Revvity has a direct presence in 2 countries.

Revvity has 4 subsidiaries including BioLegend, Horizon Discovery and Immunodiagnostic Systems.

They are in:

• Biotechnology40%
• Healthcare20%
• Other40%

View the org chart displaying its 59 main executives

Most searched biographies at Revvity

• Prahlad Singh, Chief Executive Officer and Director
• Pascale Witz, Director
• Frank Witney, Director

Popular executive movements at Revvity

• Sophie Vandebroek has joined the company as Director  (posted on January 26 2024).
• Michael Klobuchar has joined the company as Director  (posted on January 26 2024).

Create your alert
to follow the executive moves at Revvity.

Revvity has 1,816 competitors including Siemens Healthineers (Germany), IQVIA (United States (USA)) and Saint Francis Health System (United States (USA)).

Popular M&A news in Healthcare

• Midi Health has just announced a $60 Million fundraising (posted on April 29 2024).
• Xaira Therapeutics becomes a unicorn with its fundraising of $1,000 Million. (posted on April 25 2024).
• Two Chairs has just announced a $72 Million fundraising (posted on April 18 2024).

Popular contacts in Healthcare

• Ari Bousbib - Chairman and Chief Executive Officer at IQVIA
• Ralph De La Torre - Chairman and Chief Executive Officer at Steward Health Care
• Sima Sistani - Chief Executive Officer and Director at WW International

Learn more about the Healthcare industry >

Press releases by Revvity

• Revvity Signals Software’s New Synergy Solution Redefines Collaboration Between Pharma and Contract Partners
• Revvity To Hold Earnings Call on Monday, April 29, 2024
• Preliminary Injunction Granted to Enforce Revvity’s Rights and Cloud Software Group’s Obligations Related to Spotfire Software
• Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication
• Revvity Files Complaint and Seeks Injunctive Relief Against Cloud Software Group
• Revvity Introduces New Workflow to Accelerate Newborn Sequencing Research
• Revvity to Present at Upcoming Investor Conferences
• Revvity Showcases Cutting-Edge Solutions at SLAS2024
• Revvity Launches EONIS Q System Enabling Faster, Simplified Newborn Screening for SMA and SCID
• Revvity and Element Biosciences Announce Collaboration to Improve Next Generation Sequencing Research Workflow
• View more press releases Close

Social media about Revvity

• Revvity on Wikipedia, Google News & Yahoo Finance
• Revvity on LinkedIn, Twitter & YouTube

Contact by email its executives including Prahlad Singh

Call Revvity at +1 781...

View the org chart

Register to receive your alert

Report an error